Patrick Cohen

844 total citations
26 papers, 556 citations indexed

About

Patrick Cohen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Patrick Cohen has authored 26 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Patrick Cohen's work include Advanced Breast Cancer Therapies (11 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Treatment and Pharmacology (6 papers). Patrick Cohen is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Treatment and Pharmacology (6 papers). Patrick Cohen collaborates with scholars based in France, United States and Spain. Patrick Cohen's co-authors include Itzhak Rosner, M Nahir, Boulos Haraoui, Jean‐Pierre Pelletier, André Beaulieu, Michael Yaron, D. Choquette, A Taccoen, Anthony W. Tolcher and David Armstrong and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Patrick Cohen

24 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Cohen France	12	209	141	135	96	91	26	556
Eung‐Seok Lee South Korea	8	246 1.2×	81 0.6×	164 1.2×	55 0.6×	17 0.2×	15	572
Bastiaan P. van Rees Netherlands	15	264 1.3×	243 1.7×	171 1.3×	116 1.2×	20 0.2×	20	949
Long Ma China	11	136 0.7×	90 0.6×	221 1.6×	36 0.4×	50 0.5×	25	522
Juan José Mora Román Costa Rica	13	199 1.0×	140 1.0×	230 1.7×	83 0.9×	13 0.1×	32	716
Atsushi Kawabe Japan	15	239 1.1×	81 0.6×	270 2.0×	91 0.9×	8 0.1×	24	643
Jianjin Huang China	11	117 0.6×	105 0.7×	134 1.0×	81 0.8×	28 0.3×	25	338
Xiqiang Cai China	11	154 0.7×	85 0.6×	385 2.9×	225 2.3×	14 0.2×	14	616
Setsuo Tamai Japan	17	94 0.4×	217 1.5×	131 1.0×	83 0.9×	27 0.3×	46	1.1k
Greta Cipriani Italy	7	325 1.6×	87 0.6×	166 1.2×	51 0.5×	25 0.3×	7	529

Countries citing papers authored by Patrick Cohen

Since Specialization

Citations

This map shows the geographic impact of Patrick Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Cohen more than expected).

Fields of papers citing papers by Patrick Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Cohen. The network helps show where Patrick Cohen may publish in the future.

Co-authorship network of co-authors of Patrick Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Cohen. A scholar is included among the top collaborators of Patrick Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Cohen. Patrick Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Comets, Emmanuelle, et al.. (2024). Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials. CPT Pharmacometrics & Systems Pharmacology. 13(6). 941–953. 2 indexed citations

Cortés, Javier, Sara A. Hurvitz, Joyce O’Shaughnessy, et al.. (2024). Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of Clinical Oncology. 42(22). 2680–2690. 7 indexed citations

Tolaney, Sara M., Arlene Chan, Katarína Petráková, et al.. (2023). AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Journal of Clinical Oncology. 41(24). 4014–4024. 37 indexed citations

Bardia, Aditya, Sarat Chandarlapaty, Hannah M. Linden, et al.. (2022). AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nature Communications. 13(1). 4116–4116. 40 indexed citations

Campone, Mario, Sarat Chandarlapaty, Aditya Bardia, et al.. (2022). Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Cancer Research. 82(4_Supplement). OT2–11. 1 indexed citations

Bardia, Aditya, Javier Cortés, Sara A. Hurvitz, et al.. (2022). AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer. Therapeutic Advances in Medical Oncology. 14. 4287495988–4287495988. 25 indexed citations

Chandarlapaty, Sarat, Hannah M. Linden, Patrick Neven, et al.. (2022). Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer. Cancer Research. 82(4_Supplement). P1–17. 6 indexed citations

Chandarlapaty, Sarat, Hannah M. Linden, Patrick Neven, et al.. (2021). AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).. Journal of Clinical Oncology. 39(15_suppl). 1058–1058. 13 indexed citations

Chandarlapaty, Sarat, Hannah M. Linden, Patrick Neven, et al.. (2021). 264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC). Annals of Oncology. 32. S476–S477. 3 indexed citations

10.

Cohen, Patrick. (2019). Les enjeux de la réglementation du Code de déontologie. Le Journal des psychologues. n° 366(4). 25–29. 1 indexed citations

11.

Cohen, Patrick. (2019). Réglementer la déontologie, enfin !. Le Journal des psychologues. n° 366(4). 12–12.

12.

Blay, Jean‐Yves, Zsuzsanna Pápai, Anthony W. Tolcher, et al.. (2015). Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 16(5). 531–540. 58 indexed citations

13.

Sessa, Cristiana, Patricia LoRusso, Anthony W. Tolcher, et al.. (2013). Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(17). 4832–4842. 42 indexed citations

14.

Ong, Michael, Gianluca Del Conte, Rastislav Bahleda, et al.. (2013). A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2535–2535. 3 indexed citations

15.

Taylor, Mélissa, Fanny Billiot, Virginie Marty, et al.. (2012). Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells. Cancer Discovery. 2(5). 434–449. 37 indexed citations

16.

Thomson, A. B. R., et al.. (2006). Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three‐way crossover study. Alimentary Pharmacology & Therapeutics. 23(8). 1179–1187. 21 indexed citations

17.

Hunt, Richard H., David Armstrong, Cindy James, et al.. (2005). Effect on Intragastric pH of a PPI with a Prolonged Plasma Half-Life: Comparison between Tenatoprazole and Esomeprazole on the Duration of Acid Suppression in Healthy Male Volunteers. The American Journal of Gastroenterology. 100(9). 1949–1956. 67 indexed citations

18.

Provvedini, D & Patrick Cohen. (2002). [Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis].. PubMed. 31(39 Pt 2). 4S13–5. 7 indexed citations

19.

Matise, Tara C., Ravi Sachidanandam, Andrew G. Clark, et al.. (2002). A high-resolution human SNP linkage map. Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory). 2 indexed citations

20.

Pelletier, Jean‐Pierre, Michael Yaron, Boulos Haraoui, et al.. (2000). Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial. Arthritis & Rheumatism. 43(10). 2339–2348. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact